Menu Menu

News

Topics
Featured
COVID-19 Research Pipeline

216,681

Registered/ Published

4,604

Registered

793

Published

8,000

Registered
As at 23 June 2023
FILTERED BY > Tixagevimab plus cilgavimab (Evusheld) Clear filter

Communique #81

26 April, 2023
Click for the latest news:
Communique

Communique #80

27 March, 2023
Click for the latest news: 
Communique

Communique #72

27 September, 2022
Click for the latest Taskforce news: 
Communique

Communique #71

16 September, 2022
Click for the latest Taskforce news: 
Communique

Communique #70

17 August, 2022
Click for the latest Taskforce news:   
Communique

Communique #69

2 August, 2022
Click for the latest Taskforce news: 
Communique

Vaccine language changes in paediatric and pregnancy recommendations

2 August, 2022
Further to recent changes to vaccine status across the recommendations for adults with mild COVID-19, the following paediatric and pregnancy recommendations have now been updated: Nirmatrelvir plus ritonavir...
News

Communique #68

22 July, 2022
Click for the latest Taskforce news: 
Communique

Update to recommendations for adults with mild COVID-19

21 July, 2022
To reflect changing language from ATAGI and to remove confusion among clinicians about what ‘up-to-date’ with vaccination means, the Taskforce has replaced this terminology across all relevant adult...
News

Communique #61

25 March, 2022
Click for the latest Taskforce news: 
Communique

Taskforce notes TGA provisional approval for Evusheld

25 February, 2022
The Taskforce notes that on Friday, February 24, 2022, the Therapeutic Goods Administration (TGA) granted provisional approval for tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis (prevention). Taskforce guidance...
News